BRISBANE, Australia and CARLSBAD, Calif., Aug. 10, 2016 /PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced that Scripps Health will use the SOZOTM device in a validation study for monitoring patients with heart failure who are currently being tracked using pulmonary artery pressure monitoring. The validation study will provide real-world data necessary for the final design of the pivotal trial.
The study is being led by J. Thomas Heywood, MD, Director, Heart Failure Recovery and Research Program, and Andrew Accardi, MD, Chairman of Emergency Medicine. Both physicians are members of Scripps Health and ImpediMed's Medical Advisory Board. Dr. Heywood's patients at Scripps Green Hospital, part of the Scripps Health system, will be recruited for the study.
Richard Carreon, ImpediMed's Managing Director and CEO stated, "We are pleased to be partnering with Scripps Green Hospital, one of the top cardiovascular hospitals in the United States, for this exciting next step on ImpediMed's journey."
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/scripps-to-use-sozo-in-heart-failure-study-300311795.html
SOURCE ImpediMed Limited